Oppenheimer analyst Ken Wong lowered the firm’s price target on Bill (BILL) to $90 from $110 and keeps an Outperform rating on the shares. The firm notes the company delivered Q2 top line slightly ahead of expectations and raised the midpoint of full-year revenue by $10M. However, Oppenheimer expects shares will encounter pressure on concerns that noisy monetization and softer Q3 outlook could put management’s 20% growth target in FY26 at risk.